Adipotide.
Adipotide (FTPP, also called prohibitin-targeting peptide-1) is an experimental chimeric peptidomimetic designed to destroy the blood supply of white fat rather than act as a hormone.
Adipotide (FTPP, also called prohibitin-targeting peptide-1) is an experimental chimeric peptidomimetic designed to destroy the blood supply of white fat rather than act as a hormone. Adipotide is research / preclinical, and PepCue grades its published evidence F tier (21/100). Also known as FTPP. This is a research reference, not medical or dosing advice.
What it is
Adipotide (FTPP, also called prohibitin-targeting peptide-1) is an experimental chimeric peptidomimetic designed to destroy the blood supply of white fat rather than act as a hormone. It was developed by Kolonin, Arap and Pasqualini and colleagues as a proof-of-concept anti-obesity agent that targets the vasculature feeding adipose tissue. Adipotide has only ever been tested in animals; it has never completed human clinical trials and is not a medicine. It is discussed here strictly as a preclinical research compound.
How it works
Adipotide links two functional parts: a homing peptide (sequence CKGGRAKDC) that binds prohibitin, a protein found in unusual abundance on the endothelial cells of white-fat blood vessels, and a pro-apoptotic sequence (a KLAKLAK-type domain) that triggers programmed cell death once internalized. By selectively killing the endothelial cells that supply fat depots, the peptide is intended to starve and shrink adipose tissue. This vascular-targeting approach is fundamentally different from appetite- or metabolism-based drugs like GLP-1 agonists. The concept was first demonstrated in rodents before testing in primates.
Mechanism pathways
Acting directly on fat tissue to increase fat breakdown or reduce its blood supply.
This pathway groups compounds that act on adipose tissue itself rather than on appetite. Lipolysis is the enzymatic breakdown of stored triglycerides into free fatty acids and glycerol, executed by adipose triglyceride lipase and hormone-sensitive lipase inside the fat cell. It is normally triggered by catecholamines acting on beta-adrenergic receptors, which raise cyclic AMP and activate protein kinase A. Growth hormone also stimulates lipolysis, but it does so as part of a package that includes growth promotion and a rise in insulin resistance. Several compounds here derive from the observation that growth hormone's fat-mobilising activity appears to reside in the carboxy-terminal region of the molecule, separate from the domain that binds and activates the growth hormone receptor. Isolating that region was intended to produce fat breakdown without raising IGF-1 or impairing glucose handling. Mechanistic work in rodents linked the effect to beta-3 adrenergic receptor activity rather than to growth hormone receptor signalling. One member of this group is the plain fragment; another is a modified analog with an added amino-terminal residue and considerably more development history behind it. A second, entirely different approach targets the blood supply instead of the fat cell. A homing sequence binds prohibitin, a protein unusually abundant on the endothelial cells lining blood vessels within white adipose tissue, and delivers a pro-apoptotic sequence that kills those cells once internalised. The intent is to shrink fat depots by starving them of perfusion. This is a vascular-targeting strategy borrowed from oncology and is conceptually unrelated to lipolysis. A third approach targets an enzyme, nicotinamide N-methyltransferase, which is highly expressed in adipose tissue and consumes both nicotinamide and methyl groups from S-adenosylmethionine. Inhibiting it is proposed to spare nicotinamide for NAD+ regeneration and to shift adipocytes toward energy expenditure rather than storage. Clinical relevance across this group is weak. The growth hormone fragment analog was carried into human obesity trials and did not produce clinically meaningful weight loss beyond placebo, and it was not approved as a medicine. The plain fragment has essentially no human evidence of its own and borrows its reputation from that analog. The vascular-targeting compound raised kidney toxicity concerns in primate work and did not progress. The enzyme inhibitor's downstream logic is plausible but largely inferred from animal and cell studies. None of these are approved for any use.
The evidence
The original concept was shown in a mouse study by Kolonin and colleagues in Nature Medicine (2004), in which targeted ablation of adipose vasculature reduced fat mass. The most cited primate work, by Barnhart and colleagues in Science Translational Medicine (2011), treated spontaneously obese rhesus monkeys with adipotide for 28 days and reported roughly 7-15% body-weight loss along with reduced body fat on imaging and improved insulin resistance, while untreated controls were unchanged. These findings were promising but limited to small animal cohorts. Both studies share the constraints of early preclinical work: small numbers of animals, short exposure, no blinding comparable to a clinical trial, imaging and biochemical surrogates rather than clinical endpoints, and no follow-up long enough to show whether fat loss persists once treatment stops or whether ablated adipose vasculature regenerates. No completed, peer-reviewed human efficacy trials exist, and marketed or clinical human data are absent. All human-facing claims about adipotide therefore rest on animal data only. The gap is total rather than partial: there is no published human pharmacokinetic profile, no established human tolerated exposure, no efficacy signal in people, and no regulatory review of any human dataset. That places adipotide in a different category from approved obesity pharmacotherapy. Drugs such as semaglutide and tirzepatide reached approval through multi-thousand-participant randomised Phase 3 programs with blinded comparators, adjudicated safety events and, in semaglutide's case, dedicated cardiovascular outcome data, and their weight-loss estimates come from human trials rather than extrapolation from monkeys. Any comparison of adipotide's reported primate weight change with those human results is not a like-for-like comparison, and the current literature on adipotide is largely mechanistic and vascular-targeting research rather than obesity therapeutics. Nothing published to date establishes that the approach translates from rodents and monkeys to people at all.
The evidence, in brief
A chimeric peptidomimetic that homes to prohibitin on white-fat blood vessels and triggers apoptosis there, destroying the blood supply of adipose tissue rather than acting as a hormone. The headline results are animal-only: fat ablation in mice and roughly 7 to 15% weight loss in obese rhesus monkeys over 28 days. That primate study also found dose-dependent kidney tubular toxicity, and adipotide has never completed a human trial or been approved anywhere.
- Barnhart KF et al.: A peptidomimetic targeting white fat causes weight loss in obese monkeysSci Transl Med, 2011 (PMID 22072637)
- Kolonin MG et al.: Reversal of obesity by targeted ablation of adipose tissueNat Med, 2004 (PMID 15133506)
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #003
Mostly preclinical or mechanistic; little human data.
Findings come mainly from animal models, not people.
Claim receipts
Popular claims about Adipotide, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
The vascular-ablation concept has been demonstrated only in mice and in a small primate study.
The weight figures come from a short obese-monkey study; no human efficacy trial has been completed.
The primate study identified dose-dependent kidney tubular toxicity at the same exposures that produced the weight loss.
Human development never advanced, and there is no published human pharmacokinetic or efficacy dataset.
Safety profile
The pivotal primate study identified dose-dependent renal toxicity, specifically renal tubular changes, as the main safety signal at doses that produced meaningful weight loss; these kidney effects were a major reason human development did not advance. That finding matters because it appeared at exposures tied to the desired effect rather than only at extreme excess, which is the pattern that most often halts a candidate before first-in-human work. Because adipotide has not been through human trials, its safety in people is unknown and unvalidated. No human dose has been shown to be tolerated, there is no characterised human adverse-event profile, no drug-interaction data, and no evidence about what monitoring would even detect harm early. A legitimate first-in-human program for a pro-apoptotic vascular-targeting agent of this kind would require intensive renal function monitoring, careful dose escalation with stopping rules, and independent safety oversight, none of which applies to informal use. Material sold online as research chemical is unregulated and not quality-controlled, meaning the identity, potency, purity, endotoxin content and sterility of the vial are unverified, and there is no manufacturer accountable for a bad batch or any channel for reporting injury. Adipotide is not approved for human use in any jurisdiction, and the combination of a known organ-toxicity signal in primates with an unregulated supply chain is the central safety consideration for this compound.
Compound notes
- Adipotide (also called prohibitin-targeting peptide-1) is an experimental chimeric peptidomimetic that attacks the blood supply of white fat rather than acting as a hormone.
- It links a homing peptide that binds prohibitin, unusually abundant on white-adipose endothelium, to a pro-apoptotic sequence that triggers cell death once internalized.
- In obese rhesus monkeys treated for 28 days it produced roughly 7-15% body-weight loss with reduced body fat on imaging and improved insulin resistance; the concept was first shown in mice in 2004.
- It has never completed human clinical trials, so every human-facing claim rests on animal data only.
GLP-1 agonists work through appetite and metabolism. Adipotide instead kills the endothelial cells feeding fat depots, a fundamentally different and far less validated approach.
- The pivotal primate study found dose-dependent renal toxicity (renal tubular changes) at levels producing meaningful weight loss, a major reason human development did not advance.
- Safety in people is unknown and unvalidated; there is no approval in any jurisdiction.
- Material sold as a research chemical is unregulated and not quality-controlled.
Regulatory status
Adipotide is a preclinical/research compound with no FDA, EMA, or other regulatory approval for any use. It is not an approved drug or supplement, and no legitimate human therapeutic product exists. Any human use would be unapproved and unstudied.
Sold research-use-only; human evidence is limited or preclinical.
By the numbers
- 01Chimeric peptidomimetic that targets fat-tissue blood vessels, not a hormone
- 02Homes to prohibitin on white-adipose endothelium, then triggers apoptosis
- 03Concept first shown in mice (Kolonin, Nature Medicine 2004)
- 04Obese rhesus monkeys lost ~7-15% body weight over 28 days (2011)
- 05Caused dose-dependent renal (kidney tubular) toxicity in primates
- 06Never completed human trials; not approved anywhere
Adipotide: research formats
Choose the format you are researching to see route-specific notes.
Tested only in animals. It has never completed human trials, so no human administration format exists.
Adipotide is a chimeric peptidomimetic designed to kill the blood vessels feeding white fat rather than act as a hormone. Every result attributed to it comes from mice and from a 28-day study in obese rhesus monkeys. It has never completed human clinical trials, so there is no route, schedule, or exposure level established in people, and this page presents no example concentration math.
The primate study is the reason to take the absence of a human format seriously rather than as a formality: adipotide caused dose-dependent renal tubular toxicity in monkeys, and that finding is part of why it did not advance.
Adipotide has no approval from any regulator and no legitimate human therapeutic product exists. Any human use would be both unapproved and unstudied.
Sources
Every factual claim above resolves to a real, published source.
- A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeysBarnhart et al., Science Translational Medicine, 2011 · PMID 22072637
- Reversal of obesity by targeted ablation of adipose tissueKolonin et al., Nature Medicine, 2004 · PMID 15133506
- Adipotide / prohibitin-targeting peptide research (PubMed search)PubMed search results
- Adipotide human clinical trial registrations (ClinicalTrials.gov search)ClinicalTrials.gov registry search
- Prohibitin-targeting peptide and adipose vascular ablation literature (PubMed search)PubMed search results
Cite this page
PepCue. “Adipotide: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/adipotide.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.